https://blueblood.com.tw/wp-content/uploads/2024/09/3d-render-medical-background-with-dna-strands-connecting-dots-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302016-07-01 12:00:572025-06-27 09:55:59BB-101 passed Phase I clinical trials by the US FDA, eliminating risks of urinary flatworm infections during treatment.
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302016-06-01 12:00:082025-06-27 10:03:36Focused on developing drugs to promote wound healing for diabetic patients.
BB-101 passed Phase I clinical trials by the US FDA, eliminating risks of urinary flatworm infections during treatment.
TVBS reported on Blue Blood Biotech’s ‘dissolvable needle trial’ for developing drugs targeting diabetic ulcers.
Focused on developing drugs to promote wound healing for diabetic patients.